BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Stock Has Consensus Price Target of $35.00 According to Brokerages

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $35.00.

A number of research firms recently weighed in on BLSM. Guggenheim upped their target price on shares of BlossomHill Therapeutics from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Leerink Partners lifted their price target on BlossomHill Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, September 21st. Zacks Research upgraded BlossomHill Therapeutics to a “hold” rating in a research note on Wednesday, September 2nd. JPMorgan Chase & Co. began coverage on BlossomHill Therapeutics in a report on Tuesday, September 1st. They set an “overweight” rating and a $28.00 price objective for the company. Finally, Wall Street Zen downgraded BlossomHill Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 3rd.

Insider Activity at BlossomHill Therapeutics

In related news, Director Carl L. Gordon purchased 625,000 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was acquired at an average cost of $16.00 per share, with a total value of $10,000,000.00. Following the transaction, the director owned 2,714,279 shares of the company’s stock, valued at $43,428,464. This represents a 29.91% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John P. Schmid purchased 6,000 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was bought at an average cost of $16.00 per share, with a total value of $96,000.00. Following the completion of the transaction, the director directly owned 6,000 shares in the company, valued at $96,000. The trade was a ? increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 1,573,900 shares of company stock valued at $25,181,900 over the last 90 days.

BlossomHill Therapeutics Stock Up 1.7%

Shares of BLSM stock opened at $14.40 on Wednesday. BlossomHill Therapeutics has a 12 month low of $12.93 and a 12 month high of $27.99. The company has a market cap of $457.63 million and a price-to-earnings ratio of -1.65. The company’s fifty day simple moving average is $19.21.

BlossomHill Therapeutics (NASDAQ:BLSM) last issued its quarterly earnings data on Friday, September 18th. The company reported ($8.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($7.91). Research analysts anticipate that BlossomHill Therapeutics will post -5.54 EPS for the current year.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.